Amendment 29: DRIVe EZ Broad Agency Announcement

EZBAA-22-100-SOL-00003

Amendment #029

Office of Biomedical Advanced Research and Development Authority Division of Research, Innovation & Ventures (DRIVe)
Easy Broad Agency Announcement EZBAA-22-100-SOL-00003

The purpose of Amendment #029 is the following:

1) Pause the following Area of Interest (AOI):
AOI #16: Lab at Home
2) Update the closing date for the following Area of
Interest (AOI):
AOI #19: Healing Lungs
3) Revise the following Area of Interest (AOI):
AOI #19: Healing Lungs

EZBAA-22-100-SOL-00003

Amendment #029

4) Update the closing date for the following Area of
Interest (AOI):

AOI #24: RePAIR

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Pausing the following research Area of Interest (AOI):
AOI #16: Lab at Home

2)

Updating the closing date for the following research Area of Interest (AOI): AOI #19: Healing Lungs

3)

Revising the following research Area of Interest (AOI): AOI #19: Healing Lungs
We are now seeking abstract submissions for the following AOI:

AOI #19: Healing Lungs
Acute respiratory distress syndrome (ARDS) is a serious lung condition caused by multiple factors, including viral and bacterial infections, exposure to toxic radiation or chemicals, smoke inhalation, as well as trauma and severe chest injury. ARDS is characterized by an acute and diffuse lung inflammation associated with alveolar fluid accumulation and surfactant dysfunction, which results in improper lung function, leading to low blood oxygen and, in severe cases, causing lung tissue scarring and permanent respiratory impairment. Mechanical ventilation, which is currently the first-line intervention for ARDS patients, often results in further lung injury. Patients who do not respond to mechanical ventilation are more and more frequently placed on veno-venous extracorporeal membrane oxygenation (VV-ECMO), an intervention that remains labor-intensive, and costly, requiring highly specialized personnel, and prone to risks and complications. The Division of Research, Innovation, and Ventures (DRIVe) is interested in developing novel technologies to sustain healthy oxygenation levels in ARDS patients, as they heal naturally or await lung transplant, all the while preventing further tissue injury to already damaged lungs, and in advancing solutions for patients refractory to

EZBAA-22-100-SOL-00003

Amendment #029

mechanical ventilation. DRIVe is seeking two types of novel technological solutions for severe